Inhibitor Therapeutics, Inc. (INTI)
D
Pipeline Grade
Financial Position (from SEC Filings)
$1.3M
Cash & Equivalents
$1.1M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$14M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-30 | Phase2 Readout | — |
| 2026-07-30 | Phase1 Readout | — |
| 2026-07-31 | Phase1 Readout | — |
| 2026-07-31 | Phase2 Readout | — |
| 2026-08-01 | Phase2 Readout | — |
| 2026-08-01 | Phase1 Readout | — |
| 2026-08-24 | Phase3 Readout | — |
| 2026-09-01 | Phase2 Readout | — |
| 2026-09-01 | Phase2 Readout | — |
| 2026-09-02 | Phase1 Readout | — |
| 2026-09-30 | Phase2 Readout | — |
| 2026-10-01 | Phase2 Readout | — |
| 2026-10-13 | Phase2 Readout | — |
| 2026-10-15 | Phase1 Readout | — |
| 2026-10-30 | Phase2 Readout | — |
| 2026-10-31 | Phase1 Readout | — |
| 2026-10-31 | Phase1 Readout | — |
| 2026-10-31 | Phase1 Readout | — |
| 2026-11-01 | Phase2 Readout | — |
| 2026-11-01 | Phase2 Readout | — |
Active Clinical Trials (50)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06599619 | Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi | OTHER | Recruiting | 30 |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | PHASE4 | Recruiting | 15 |
| NCT07214532 | Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | OTHER | Recruiting | 725 |
| NCT05785897 | STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT | OTHER | Recruiting | 350 |
| NCT06604897 | Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension | OTHER | Active Not Recruiting | 1,405 |
| NCT02843633 | LEADERS FREE II: BioFreedom™ Pivotal Study | OTHER | Active Not Recruiting | 1,203 |
| NCT07059494 | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | PHASE4 | Recruiting | 40 |
| NCT06125795 | A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocyti... | OTHER | Active Not Recruiting | 146 |
| NCT06595290 | Vietnamese Rapid Acceleration Protocol for Intensifying Drug Therapy in Heart Failure With Reduced Ejection Fraction | OTHER | Recruiting | 500 |
| NCT04510129 | A Multicenter Cancer Biospecimen Collection Study | OTHER | Recruiting | 1,650 |
| NCT04291755 | Development and Analysis of a Stool Bank for Cancer Patients | OTHER | Recruiting | 100 |
| NCT03432520 | Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A | OTHER | Active Not Recruiting | 29 |
| NCT06077422 | Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | PHASE3 | Enrolling By Invitation | 150 |
| NCT04565054 | Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC | PHASE3 | Active Not Recruiting | 1,260 |
| NCT02502266 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Pl... | PHASE3 | Active Not Recruiting | 582 |
| NCT07109414 | Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) | PHASE3 | Active Not Recruiting | 380 |
| NCT06580314 | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | PHASE3 | Recruiting | 880 |
| NCT06440967 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy | PHASE3 | Active Not Recruiting | 984 |
| NCT05365178 | To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulves... | PHASE3 | Active Not Recruiting | 432 |
| NCT05183646 | A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB | PHASE3 | Recruiting | 286 |
| NCT05513001 | An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patie... | PHASE3 | Active Not Recruiting | 696 |
| NCT07000357 | A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a... | PHASE3 | Recruiting | 15,100 |
| NCT04530565 | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL... | PHASE3 | Active Not Recruiting | 348 |
| NCT06614192 | A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Pa... | PHASE3 | Active Not Recruiting | 74 |
| NCT05948475 | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | PHASE3 | Recruiting | 200 |
| NCT07614958 | Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipide... | PHASE3 | Recruiting | 426 |
| NCT01874353 | Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | PHASE3 | Active Not Recruiting | 327 |
| NCT06461897 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in... | PHASE3 | Recruiting | 675 |
| NCT06630299 | Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People ... | PHASE3 | Active Not Recruiting | 600 |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | PHASE3 | Recruiting | 400 |
| NCT06382948 | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | PHASE3 | Recruiting | 240 |
| NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Particip... | PHASE3 | Recruiting | 1,050 |
| NCT05502341 | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a... | PHASE3 | Active Not Recruiting | 689 |
| NCT05405166 | SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM | PHASE3 | Active Not Recruiting | 531 |
| NCT05437263 | A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis | PHASE3 | Active Not Recruiting | 241 |
| NCT07062965 | A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive,... | PHASE3 | Recruiting | 400 |
| NCT07220083 | A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosc... | PHASE3 | Recruiting | 286 |
| NCT04169997 | A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | PHASE3 | Active Not Recruiting | 404 |
| NCT04662255 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | PHASE3 | Active Not Recruiting | 500 |
| NCT07342478 | ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL | PHASE3 | Recruiting | 306 |
| NCT03673501 | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | PHASE3 | Active Not Recruiting | 453 |
| NCT04637594 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | PHASE3 | Active Not Recruiting | 3 |
| NCT06632327 | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc... | PHASE3 | Recruiting | 1,100 |
| NCT05389449 | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Par... | PHASE3 | Active Not Recruiting | 80 |
| NCT06087835 | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Partici... | PHASE3 | Active Not Recruiting | 1,835 |
| NCT06206733 | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma | PHASE3 | Active Not Recruiting | 780 |
| NCT02821013 | Duration of Anti-PD-1 Therapy in Metastatic Melanoma | PHASE3 | Recruiting | 614 |
| NCT05156983 | A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery | PHASE3 | Recruiting | 440 |
| NCT06493552 | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | PHASE3 | Recruiting | 700 |
| NCT06699212 | A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurre... | PHASE3 | Recruiting | 412 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.